International Journal of Medical and Health Research
www.medicalsciencejournal.com
ISSN: 2454-9142
Received: 30-07-2025, Accepted: 29-08-2025, Published: 16-09-2025
Volume 11, Issue 5, 2025, Page No. 1-5

Interstitial lung disease: A comprehensive clinical and public health perspective

Dr. Rajendra Tatu Nanavare[1], Dr. Pradeepkumar Kapsiker[2]
[1] Department of Medical, Faculty for Post Graduate Diploma in Chest and Tuberculosis, Group of TB Hospital Sewri Mumbai, College of Physician and Surgeon CPS Mumbai, Maharashtra, India
[2] Department of Medical, Group of TB Hospital Sewri Mumbai, Maharashtra, India

Abstract
Background: Interstitial Lung Disease (ILD) comprises a diverse group of parenchymal lung disorders characterized by inflammation, fibrosis, and progressive respiratory impairment. It represents a rising global health challenge, with significant burden in India due to occupational exposures, biomass fuels, tuberculosis sequelae, and post-COVID fibrosis.
Objective: To provide a comprehensive clinical and public health perspective on ILD, including its pathology, epidemiology, diagnostic strategies, management across etiologies and severity, occupational health implications, and preventive measures.
Methods: A narrative academic review synthesizing current literature, clinical guidelines, and case-based experiences. Special emphasis is placed on diagnostic assessment, pharmacologic and non-pharmacologic management, occupational ILDs, and post-infectious sequelae such as pulmonary tuberculosis and COVID-19.
Results: ILDs present with overlapping features but require precise diagnostic tools such as high-resolution computed tomography (HRCT), pulmonary function tests, and multidisciplinary discussions. Antifibrotic therapies (pirfenidone, nintedanib) have improved outcomes in idiopathic pulmonary fibrosis, while corticosteroids and immunosuppressants remain central for hypersensitivity pneumonitis and connective tissue disease–associated ILD. Occupational ILDs (silicosis, asbestosis, byssinosis, farmer's lung) remain prevalent and underdiagnosed, necessitating preventive workplace interventions. Post-infectious sequelae, particularly after TB, pneumonia, and COVID-19, are emerging contributors to the ILD burden. Early recognition, exposure control, pulmonary rehabilitation, and multidisciplinary care improve prognosis.
Conclusion: ILD is a multifactorial disease group with high morbidity and mortality. Timely diagnosis, targeted therapies, occupational health reforms, and public awareness are crucial to reducing its impact. Strengthened surveillance and preventive strategies in high-risk populations can significantly reduce disease progression and improve patient outcomes.

Keywords: Interstitial lung disease, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, occupational ild, pulmonary tuberculosis, Post-COVID fibrosis, antifibrotics, public health, prevention

Introduction

Interstitial Lung Disease (ILD) represents a heterogeneous group of diffuse parenchymal lung disorders characterized by varying degrees of inflammation and fibrosis of the alveolar walls, interstitium, and capillary endothelium. The spectrum includes idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP), connective tissue disease–associated ILD (CTD-ILD), sarcoidosis, pneumoconiosis, and drug-induced ILD. The common pathway across these disorders is impaired gas exchange, progressive dyspnea, and eventual respiratory failure. ILD has emerged as a global health challenge due to its rising incidence, complex etiology, and poor prognosis if not detected early.

Overview and Historical Background

The recognition of ILD dates back to the late 19th and early 20th centuries, when industrialization led to the identification of "dust lung diseases" such as silicosis and asbestosis. In the 1960s, pathologists described "cryptogenic fibrosing alveolitis," which was later classified as idiopathic pulmonary fibrosis. Over the decades, advances in imaging (HRCT), pulmonary pathology, and molecular biology refined ILD into more than 200 distinct entities. Landmark consensus guidelines from the American Thoracic Society (ATS) and European Respiratory Society (ERS) in the early 2000s standardized diagnostic categories and clinical practice.

Pathology

Pathologically, ILD involves inflammation and fibrosis of the alveolar interstitium:

- **Inflammatory stage:** infiltration by lymphocytes, plasma cells, and macrophages.
- **Fibrotic stage:** proliferation of fibroblasts and deposition of collagen leading to thickened alveolar walls.
- **Honeycombing:** advanced fibrosis causing cystic air spaces, loss of lung compliance, and severe hypoxemia.

The histopathological patterns include usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP), organizing pneumonia, desquamative interstitial pneumonia (DIP), and lymphoid interstitial pneumonia (LIP).

Pathophysiology and Pathogenesis

The pathophysiology of ILD is multifactorial:

- **Injury:** Repeated micro-injuries to alveolar epithelium by dusts, fumes, antigens, infections, or autoimmune activity.
- **Inflammation:** Cytokine release (IL-1, TNF-α, TGF-β) triggers infiltration of inflammatory cells.

- **Fibrosis:** Dysregulated wound healing with excessive fibroblast activity and collagen deposition causes irreversible scarring.

- **Gas exchange impairment:** Thickened alveolar walls impair diffusion of oxygen, leading to hypoxemia, especially on exertion.

Epidemiology
- **Global prevalence:** Estimated at 70–80 cases per 100,000 population, with idiopathic pulmonary fibrosis accounting for 15–20%.

- **India:** Limited data suggest a rising prevalence due to increased detection with HRCT. Environmental exposures (biomass fuel, crop dust, industrial fumes) play a major role.

- **Risk factors:** Age >50 years, smoking, occupational exposures (coal, silica, asbestos, cotton), long-term use of drugs (amiodarone, nitrofurantoin, methotrexate), and connective tissue diseases (rheumatoid arthritis, systemic sclerosis).

Diagnostic Assessment and Investigations
A structured, multidisciplinary approach is critical to confirm ILD and exclude mimics such as infections, COPD, or cardiac disease.

1. Clinical Evaluation
- **History:** Duration of breathlessness, cough, occupational/ environmental exposure (farmers, miners, textile workers), smoking, drug history (e.g., amiodarone, nitrofurantoin), autoimmune symptoms.

- **Examination:** Fine *Velcro-like crackles*, digital clubbing, signs of connective tissue disease (skin thickening, arthritis, rash).

2. Pulmonary Function Tests (PFTs)
- **Restrictive defect:** ↓Forced Vital Capacity (FVC), ↓Total Lung Capacity (TLC).

- **Reduced diffusion:** ↓DLCO is an early and sensitive marker.

- **6-Minute Walk Test:** Exercise desaturation <88% suggests advanced disease.

3. Imaging
- **Chest X-ray:** Non-specific reticulonodular shadows.
- **High-Resolution CT (HRCT):** Gold standard.

Identifies key patterns
- **Usual Interstitial Pneumonia (UIP):** basal, subpleural honeycombing.

- **Nonspecific Interstitial Pneumonia (NSIP):** ground-glass opacities, less honeycombing.

- **Hypersensitivity Pneumonitis:** centrilobular nodules, air-trapping.

- **Sarcoidosis:** upper lobe nodularity, mediastinal lymphadenopathy.

4. Laboratory and Serology
- **Autoantibodies:** ANA, RF, anti-CCP, anti-Scl-70, ANCA (to detect CTD-ILD).
- Precipitin tests for organic antigens (HP).
- BNP, troponin, echocardiography to exclude cardiac disease.

5. Histopathology
- **Transbronchial lung biopsy (TBLB):** Limited yield, useful in sarcoidosis, HP.

- **Surgical lung biopsy or Cryobiopsy:** Considered when HRCT is inconclusive.

- Pathology reviewed in *Multidisciplinary Discussion (MDD)* with radiologist, pulmonologist, and pathologist.

Management of ILD by Type and Severity
Management requires tailoring according to etiology, disease activity, and severity.

1. General Principles
- **Remove offending exposure:** e.g., moldy hay in farmers, cotton dust in mills, asbestos.

- **Vaccination:** Influenza and pneumococcal vaccines.
- **Smoking cessation** and lifestyle modifications.

- **Pulmonary rehabilitation** to improve exercise tolerance.

2. Pharmacologic Management
a. Idiopathic Pulmonary Fibrosis (IPF)
- **Mild to moderate disease (FVC >50%, DLCO >35%):**

- ***Antifibrotic therapy*:** Pirfenidone (antioxidant, antifibrotic), Nintedanib (tyrosine kinase inhibitor).
- Shown to slow FVC decline and improve survival.

Severe disease
- Long-term oxygen therapy.
- Referral for lung transplant evaluation.

Not recommended: Corticosteroids or immunosuppressants (shown to worsen outcomes).

b. Hypersensitivity Pneumonitis (HP)
Acute/subacute HP
- Remove antigen exposure (e.g., moldy hay, bird droppings).
- Corticosteroids: Prednisone 0.5 mg/kg for 4–6 weeks, then taper.

Chronic HP with fibrosis
- Antifibrotic therapy considered (pirfenidone/nintedanib).

c. Connective Tissue Disease–Associated ILD (CTD-ILD)
- **First line:** Corticosteroids, Mycophenolate mofetil (MMF), or Azathioprine.

- **Progressive disease:** Cyclophosphamide or Rituximab.
- **Systemic Sclerosis–ILD:** Nintedanib approved to reduce decline in FVC.

d. Sarcoidosis
- Corticosteroids (prednisone 20–40 mg/day, tapered).
- Methotrexate or Azathioprine for steroid-sparing effect.
- Refractory cases: TNF-α inhibitors (Infliximab).

e. Occupational Pneumoconiosis (Silicosis, Asbestosis, Coal Worker's Lung)
- Exposure cessation and workplace protection.
- Symptomatic treatment only (no curative therapy).
- Manage complications: TB prophylaxis in silicosis, lung cancer screening in asbestosis.

3. Management by Severity

Severity	Findings	Management
Mild (FVC >70%, minimal symptoms)	HRCT shows early disease	Monitor every 6–12 months, remove exposures, pulmonary rehab, consider antifibrotics in IPF
Moderate (FVC 50–70%, DLCO 40–60%)	Dyspnea on exertion, ground-glass opacities	Antifibrotics (IPF), corticosteroids (HP, CTD-ILD), oxygen if needed
Severe (FVC <50%, DLCO <40%)	Resting hypoxemia, honeycombing, exercise limitation	Long-term oxygen therapy, antifibrotics, referral for lung transplantation
End-stage	Respiratory failure, cor pulmonale	Palliative care, symptom control, transplant in eligible patients

4. Non-Pharmacologic Support
- **Oxygen therapy:** Long-term improves survival in hypoxemic patients.
- **Pulmonary rehabilitation:** Exercise training, breathing exercises.
- **Nutritional support:** Prevents cachexia.
- **Psychological support:** ILD has significant psychosocial burden.
- **Vaccination and infection prevention.**

5. Advanced Care
- **Lung transplantation:** Definitive option for eligible advanced IPF/ILD patients.
- **Palliative care:** Symptom management (morphine for refractory dyspnea), end-of-life discussions.

Occupational Interstitial Lung Diseases and Preventive Strategies

Occupational Angle

Occupational and environmental exposures are among the most important risk factors for ILD in India and globally. Workers in agriculture, mining, textile, construction, and chemical industries face continuous inhalation of dust, fibers, and fumes, which directly injure the alveolar epithelium.

Major occupational causes include
- **Agriculture and farming:** Farmer's lung (hypersensitivity pneumonitis due to moldy hay, grains, sugarcane dust).
- **Mining and construction:** Silicosis (quartz dust), asbestosis (asbestos fibers), coal workers' pneumoconiosis.
- **Textile industry:** Byssinosis (cotton dust exposure).
- **Chemical factories:** ILD from exposure to beryllium, hard metal dusts, pesticides, and organic solvents.
- **Healthcare and laboratories:** Occupational exposure to disinfectants, formaldehyde, and drugs like methotrexate or amiodarone.

Occupational ILDs are often underdiagnosed in India due to poor workplace surveillance, lack of awareness, and overlap with common conditions like asthma and COPD.

Preventive Measures

1. At the Workplace (Primary Prevention)

Engineering controls
- Dust suppression by wet drilling and spraying water in mines.
- Local exhaust ventilation and air filters in factories.
- Mechanized harvesting and storage to reduce mold exposure in farms.

Personal Protective Equipment (PPE)
- Proper fitting N95 masks or respirators for farmers, miners, and textile workers.
- Gloves and protective clothing when handling chemicals.

Substitution of hazardous materials
- Use of safer alternatives for asbestos and toxic solvents.

2. Medical Surveillance (Secondary Prevention)
- Periodic lung function testing (spirometry, DLCO).
- Baseline and annual chest X-rays or HRCT in high-risk workers.
- Early identification of symptomatic workers and referral to chest physicians.
- Record keeping of occupational exposures.

3. Health Education and Awareness
- Training programs for farmers and factory workers on safe handling of dust and chemicals.
- Awareness among healthcare providers to ask detailed occupational history in patients with unexplained breathlessness.

4. Policy and Legal Measures (Tertiary Prevention)
- Strict enforcement of occupational safety standards (Factories Act, Mines Act).

- Compensation schemes for workers diagnosed with occupational ILD.
- Collaboration between pulmonologists, public health authorities, and labor unions for workplace reforms.

Key Preventive Message

- **For workers:** "Mask and ventilation are as important as medicine."
- **For communities:** "Safe work, safe breath."
- **For policymakers:** Investment in occupational health will reduce the ILD burden and improve productivity.

Academic Discussion

ILD is diagnostically challenging due to overlapping clinical and radiological features.

- **Clinical:** Progressive exertional dyspnea, dry cough, Velcro-like basal crackles, and digital clubbing.
- **Radiology:** HRCT is the gold standard, showing reticular opacities, ground-glass changes, traction bronchiectasis, or honeycombing.
- **Pulmonary Function Tests (PFTs):** Restrictive pattern (↓TLC, ↓VC, ↓DLCO).
- **Biopsy:** Surgical lung biopsy may be required when noninvasive findings are inconclusive.
- **Serology:** Autoimmune panels for CTD-related ILD.

Recent advances include antifibrotic drugs such as pirfenidone and nintedanib, which slow disease progression in IPF. Non-IPF ILDs may benefit from immunosuppressive therapy (corticosteroids, azathioprine, mycophenolate). Lung transplantation is an option in advanced disease.

Case Discussions

Case 1: Farmer with Hypersensitivity Pneumonitis

A 48-year-old farmer presented with progressive breathlessness and dry cough. HRCT revealed diffuse ground-glass opacities and centrilobular nodules. History confirmed chronic exposure to moldy hay. Diagnosis: Farmer's lung (HP). Management included corticosteroids and strict avoidance of antigen exposure.

Case 2: Occupational ILD – Textile Worker

A 55-year-old cotton mill worker with exertional dyspnea and fine basal crackles was diagnosed with byssinosis-related ILD. HRCT showed interstitial fibrosis. Counseling included workplace safety, protective masks, and medical management with bronchodilators and steroids.

Case 3: Idiopathic Pulmonary Fibrosis

A 62-year-old non-smoker developed worsening dyspnea over 2 years. HRCT demonstrated a UIP pattern with honeycombing. PFT revealed severe restriction. He was started on nintedanib, pulmonary rehabilitation, and supplemental oxygen.

Summary Table

Feature	ILD Characteristics
Symptoms	Progressive dyspnea, dry cough, fatigue
Risk factors	Dust, fumes, smoking, drugs, autoimmune diseases
Investigations	HRCT, PFT, biopsy, serology
Pathology	Inflammation → Fibrosis → Honeycombing
Common subtypes	IPF, HP, CTD-ILD, pneumoconiosis, sarcoidosis
Treatment	Antifibrotics, steroids, immunosuppressants, oxygen, lung transplant
Prevention	Reduce occupational exposure, early screening, protective equipment
Prognosis	Variable; IPF median survival 3–5 years without therapy

Summary

Interstitial Lung Disease (ILD) is a term used for more than 200 lung conditions where the lungs become stiff and scarred. This scarring makes it difficult for oxygen to pass into the blood, leading to breathlessness, dry cough, and fatigue. The disease can progress slowly or rapidly, and without treatment, it can cause severe disability or even death.

In India, ILD is especially important because of exposure to farm dust, smoke from cooking fuels, mining dust, textile fibers, and chemicals. Many farmers and workers are at risk of developing ILD. In addition, people who recover from tuberculosis, severe pneumonia, or COVID-19 may later develop long-term lung damage that resembles ILD.

Diagnosis requires special scans (HRCT), lung function tests, and sometimes biopsy. Modern medicines such as antifibrotic drugs can slow the disease in idiopathic pulmonary fibrosis, while steroids and immune-modifying medicines are useful in other forms. Pulmonary rehabilitation, oxygen support, and lifestyle changes also help improve quality of life.

Prevention is equally important: using protective masks, reducing dust exposure, and early medical consultation. For policymakers, investing in occupational health and public awareness is vital. With early recognition and treatment, the progression of ILD can be slowed, giving patients better survival and quality of life.

Conclusion

ILD is a complex group of lung diseases with significant morbidity and mortality. Early recognition, multidisciplinary diagnosis, and timely initiation of therapy are crucial to improve outcomes. Occupational and environmental health strategies are essential in resource-limited countries like India, where exposures to dust, biomass fuel, and chemicals remain high.

Key Message to Health Care Workers, Communities, and Stakeholders

- **For healthcare workers:** Maintain a high index of suspicion for ILD in patients with chronic breathlessness and dry cough; use HRCT and PFT early.

- **For communities:** Avoid dust and smoke exposure; use masks in farms, mines, and industries; seek medical help early.

- **For policymakers:** Strengthen occupational health policies, provide early screening programs, and improve access to antifibrotic therapies.

- **For patients and caregivers:** Adherence to treatment, lifestyle modifications, pulmonary rehabilitation, and psychological support are equally important.

References

1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, *et al*. Diagnosis of idiopathic pulmonary fibrosis: ATS/ERS/JRS/ALAT guideline. American Journal of Respiratory and Critical Care Medicine,2018:198(5):44–e68.
2. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. The Lancet Respiratory Medicine,2020:8(8):807–815.
3. Singh S, Dhooria S, Aggarwal AN, Sehgal IS, Raj R, Gupta N, *et al*. Interstitial lung diseases in India: Results of a prospective registry. American Journal of Respiratory and Critical Care Medicine,2017:195(6):801–813.
4. Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis. Time to treat. Respiratory Research,2019:20:205.
5. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole IN, Glassberg MK, *et al*. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. The New England Journal of Medicine,2014:370:2083–2092.